Results 21 to 30 of about 1,594,004 (375)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

OncoImmunology, 2021
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to engineer a
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech   +23 more
doaj   +1 more source

Therapeutic Chaos [PDF]

Journal for Person-Oriented Research, 2019
The conventional view on interventions as mechanistically causing interchangeable clients to get better has come under attack. Group-based and linear approaches fall short in adequately describing the idiosyncratic and dynamic nature of treatment processes.
Guido Strunk, Anna Lichtwarck-Aschoff
openaire   +5 more sources

Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]

, 2019
Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...
Cui, Xianshu, Dowdy, Steven F, Huggins, Ian J, Jadhav, Satish, Medina, Carlos A, Springer, Aaron D, van den Berg, Arjen   +6 more
core   +1 more source

RNA-based therapeutics: an overview and prospectus

Cell Death and Disease, 2022
The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto “undruggable” proteins, transcripts and genes, thus potentially broadening the therapeutic targets.
Yiran Zhu, Liyuan Zhu, Xian Wang, Hongchuan Jin   +3 more
semanticscholar   +1 more source

An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria

Molecular Systems Biology, 2022
Enteric hyperoxaluria (EH) is a metabolic disease caused by excessive absorption of dietary oxalate leading to the formation of chronic kidney stones and kidney failure. There are no approved pharmaceutical treatments for EH.
David Lubkowicz, Nicholas G Horvath, Michael J James, Pasquale Cantarella, Lauren Renaud, Christopher G Bergeron, Ron B Shmueli, Cami Anderson, Jian‐Rong Gao, Caroline B Kurtz, Mylene Perreault, Mark R Charbonneau, Vincent M Isabella, David L Hava   +13 more
doaj   +1 more source

Polymeric Theragnostic Nanoplatforms for Bone Tissue Engineering

Journal of Nanotheranostics, 2023
Nanomaterial-based tissue engineering strategies are precisely designed and tweaked to contest specific patient needs and their end applications. Though theragnostic is a radical term very eminent in cancer prognosis, of late, theragnostic approaches ...
Kaushita Banerjee, Harishkumar Madhyastha   +1 more
doaj   +1 more source

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]

, 2020
In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Alpini, Gianfranco, Francis, Heather, Kennedy, Lindsey, Kundu, Debjyoti, Meadows, Vik   +4 more
core   +1 more source

Impact and Advances in the Role of Bacterial Extracellular Vesicles in Neurodegenerative Disease and Its Therapeutics

Biomedicines, 2023
Bacterial Extracellular Vesicles (BEVs) possess the capability of intracellular interactions with other cells, and, hence, can be utilized as an efficient cargo for worldwide delivery of therapeutic substances such as monoclonal antibodies, proteins ...
Ashok Iyaswamy, Kejia Lu, Xin-Jie Guan, Yuxuan Kan, Chengfu Su, Jia Liu, Ravindran Jaganathan, Karthick Vasudevan, Jeyakumari Paul, Abhimanyu Thakur, Min Li   +10 more
doaj   +1 more source

Cell Therapy for Type 1 Diabetes [PDF]

, 2014
Acknowledgements The work described in this review was supported by a grant from the MRC. K.R.M. is supported by a fellowship from the Scottish Translational Medicines and Therapeutics Initiative through the Wellcome Trust.Peer reviewedPublisher ...
Docherty, H. M., Docherty, K., Lima, M. J., Muir, K. R.   +3 more
core   +1 more source

The current landscape of nucleic acid therapeutics

Nature Nanotechnology, 2021
The increasing number of approved nucleic acid therapeutics demonstrates the potential to treat diseases by targeting their genetic blueprints in vivo.
J. Kulkarni, D. Witzigmann, Sarah B. Thomson, Sam Chen, B. Leavitt, P. Cullis, R. van der Meel   +6 more
semanticscholar   +1 more source